Tevogen Bio
-
Business & Markets · Startups Tevogen Receives $1M to Accelerate AI-Driven Drug Discovery; Remains Well Capitalized to Execute Growth Strategy
Insider Brief PRESS RELEASE — Tevogen Bio Holdings Inc. (“Tevogen” or the “Company) (Nasdaq: TVGN), announced it has received the previously reported $1 million in funding to advance Tevogen.AI, its artificial intelligence–powered drug discovery and development… -
Business & Markets · Startups Tevogen Bio to Receive $8M of Non-Dilutive Grant Funding, Reiterates Efficient Operations
-
Policy & Government · Regulation Tevogen Bio Strengthens Robust IP Portfolio With Filing of Predictive AI Patent, With the Goal to Establish a Blueprint to Unlock the Full Potential of T Cell Therapies and Accelerate AI Integration to Advance Its Bold Growth Agenda
The AI economy, every weekday morning
The daily briefing plus the weekly Scale-ups to watch edition. Free, no spam, unsubscribe any time.